Researchers from the Medical University of South Carolina (MUSC) may have found a new therapeutic target for the treatment of pulmonary fibrosis using a preclinical model of the disease. The candidate protein, called insulin-like growth factor-binding protein 5 (IGFBP-5), induces lung fibrosis (scarring) early on by turning on genes…
Targeting IGFBP-5 May Be Viable Strategy to Treat Pulmonary Fibrosis, Preclinical Study Finds
So, here it is: the last of my gratitude miniseries columns for 2018. As I write this, tonight is New Year’s Eve, and I am looking forward to spending it reading each of these columns and reflecting on what a great year it has been. While many…
Throughout 2018, Pulmonary Fibrosis News provided you daily coverage of key discoveries, potential treatments, and clinical trials related to pulmonary fibrosis (PF). As we look forward to bringing more news to patients, family members, and caregivers dealing with PF in 2019, here are the Top 10 most-read articles of 2018,…
When Kim Fredrickson was diagnosed with pulmonary fibrosis (PF) four and a half years ago, she was a self-described mess. She had a disease she had never heard of, and a doctor who didn’t explain it. So naturally, she turned to the internet. She was not consoled. “I…
A study found a link between MUC5B-induced mucus accumulation and the progression of idiopathic pulmonary fibrosis, reporting that a MUC5B mutation can prevent mucus clearance in the small airways and induce scarring, indicating a strong risk factor in IPF. The study, “Muc5b overexpression causes mucociliary dysfunction and enhances…
It’s no secret that life-threatening illnesses are overwhelming. Suddenly, patients must try to understand a flood of unfamiliar information, accept psychological and physical changes, and manage numerous appointments. Due to all of that, it is essential that patients find effective coping strategies. This is not something I’ve perfected,…
Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…
Bridge Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) recently approved the company’s Investigational New Drug (IND) application for BBT-877. The company now has permission to start human clinical trials with this potential therapy for idiopathic pulmonary fibrosis (IPF). The IND application was submitted in November 2018.
Christmas is a week away, and I’ve been tired from shopping, decorating, and making plans. I’m feeling discouraged because my fatigue has prevented me from accomplishing what I want to. I’ve had to do a lot of adjusting due to my pulmonary fibrosis (PF) troubles. I love decorating, but…
Sustained-release capsules of Ofev (nintedanib), which is used to treat idiopathic pulÂmonary fibrosis (IPF), were better at reaching systemic circulation in the body than the current marketed formulation, according to a study. Findings also suggested that the sustained-release formula of Ofev increased its absorption in the gut. The study,…
